The FDA granted fast track designation to ARO-AAT, Arrowhead Pharmaceuticals’ second generation subcutaneously administered RNA interference therapeutic, for the treatment of alpha-1 antitrypsin deficiency-related liver disease, according to a press release.
Arrowhead also announced that the company is in final preparations to initiate SEQUOIA (AROAAT2001), a phase 2/3 clinical study in the U.S. and Europe, and AROAAT2002, a phase 2 open-label clinical study in Europe.
“With no currently approved agents to treat AATD-associated liver disease, alpha-1 patients and their physicians

Source link